Melanoma is the most aggressive form of skin cancer, with increasing incidence rates and poor prognosis in the presence of metastasis.1 More than half of melanomas harbour a mutation in the BRAF gene, which consists in most cases in a substitution of valine to glutamic acid in position 600 (V600E mutation).2 Two main treatment options are available for advanced melanoma patients harbouring a BRAF mutation: targeted therapies, consisting of BRAFi and MEKi, and immunotherapies. The gene discussed is BRAF; the disease is skin neoplasm.